Our aim was to investigate whether the SMART regimen would reduce the risk of overuse of agonist , reduce the likelihood of patients to seek medical review when such episodes occurred , and if any reduction in severe asthma exacerbations would be at the cost of a higher burden of systemic corticosteroid .